FGP
IART icon

Freestone Grove Partners’s Integra LifeSciences IART Stock Holding History

Freestone Grove Partners’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9 Buy
+1
New +$11 ﹤0.01% 949

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Freestone Grove Partners's IART Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Integra LifeSciences (IART) in Q1 2026: 1 share worth $9. The stake represents ﹤0.01% of the portfolio and ranks #949 among its holdings.

201 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • Freestone Grove Partners held 1 share of Integra LifeSciences worth $9 as of Q1 2026.
  • Integra LifeSciences was a new Freestone Grove Partners position in Q1 2026.
  • Integra LifeSciences made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #949 holding.
  • 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.